Gyre Therapeutics, Inc. (GYRE) — Financial statements
Income statement, balance sheet, and cash flow for Gyre Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 117↑10.2% | 106↓6.8% | 113↑10.9% | 102↑1294.0% | 7 | |
| Cost of Revenue | 5↑39.4% | 4↓16.2% | 5↓3.3% | 5↓37.5% | 8 | |
| Gross Profit | 111↑9.1% | 102↓6.4% | 109↑11.6% | 97↑29466.6% | -0.33 | |
| Operating Expenses | ||||||
| R&D Expenses | 14↑13.9% | 12↓12.7% | 14↓17.4% | 17↓74.2% | 65 | |
| General & Administrative Expenses | 21↑29.1% | 16↑9.9% | 15↓15.6% | 17 | 0.00 | |
| Selling & Marketing Expenses | 65↑13.3% | 58↓6.0% | 61↑12.8% | 54 | 0.00 | |
| SG&A Expenses | 86↑16.8% | 74↓2.9% | 76↑5.9% | 72↑280.5% | 19 | |
| Other Expenses | 0.00↓100.0% | 0.07↓99.9% | 86 | 0.00 | 0.00 | |
| Operating Expenses | 100↑16.3% | 86↓51.3% | 176↑99.4% | 88↑5.9% | 83 | |
| Total Costs & Expenses | 105↑17.3% | 90↓50.4% | 181↑94.1% | 93↑2.2% | 91 | |
| Operating Results | ||||||
| Operating Income | 11↓28.9% | 16↑124.0% | -67↓830.5% | 9↑111.0% | -84 | |
| Depreciation & Amortization | 3↑58.7% | 2↑42.5% | 1↓1.3% | 1↑289.3% | 0.29 | |
| EBITDA | 14↓21.4% | 18↓12.3% | 20↑96.7% | 10↑111.8% | -88 | |
| EBIT | 11↓29.2% | 16↓15.5% | 19↑108.8% | 9↑110.5% | -88 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑12.9% | 2↑48.2% | 1↑43.8% | 0.73↑1761.5% | 0.04 | |
| Interest Income | 2↑12.9% | 2↑48.2% | 1↑43.8% | 0.73↑1761.5% | 0.04 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.07↑99.9% | -86 | 0.00↓100.0% | 4 | |
| Other Income / Expenses | 3↓58.3% | 7↑172.5% | -10↓4757.9% | 0.21↑105.0% | -4 | |
| Income Before Tax | 14↓37.8% | 23↑130.2% | -77↓917.7% | 9↑110.7% | -88 | |
| Income Tax Expense | 5↓14.4% | 5↓37.5% | 9↑67.0% | 5 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 10↓44.8% | 18↑120.9% | -85↓2081.5% | 4↑104.9% | -88 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 5↓58.4% | 12↑113.0% | -93↓4137.1% | 2↑102.6% | -88 | |
| Bottom-Line Net Income | 2↓80.8% | 12↑113.0% | -93↓4137.1% | 2↑102.6% | -88 | |
| EPS (Basic) | 0.06↓59.8% | 0.14↑109.9% | -1.41↓4784.4% | 0.03↑101.0% | -2.87 | |
| EPS (Diluted) | 0.02↓55.0% | 0.05↑103.5% | -1.41↓4800.0% | 0.03↑101.0% | -2.87 | |
| Weighted Average Shares | 89↑5.0% | 85↑29.3% | 66↓14.2% | 77↑150.4% | 31 | |
| Weighted Average Diluted Shares | 103↑0.9% | 102↑55.4% | 66↓13.0% | 76↑147.0% | 31 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.